Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Noex vs Busonid in Allergic Persistent Rhinitis
NCT02988778Phase 3Withdrawn
- Sponsor
- Eurofarma
- Start
- Oct 2019
- Primary completion
- Oct 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of budesonide in allergic rhinitis (AR) (2 arms), sponsored by Eurofarma. Primary endpoint: Nasal Index Score at 28 days. Planned start Oct 2019; status: withdrawn.
02
Drugs
budesonide
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT02988778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02988778.